27/11/2025 09:45
Protagonist Therapeutics : Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
pstrong id=datelineNEW YORK, NY / a href=https://www.accessnewswire.com/ACCESS Newswire/a / November 27, 2025 / /strongProtagenic Therapeutics, Inc. Nasdaq:PTIX the "Company" today announced that it has received a notification letter from the Nasdaq Listing Qualifications Staff the...
06/11/2025 22:05
Protagonist Therapeutics : Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
pistrongFollowing the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency EMA application was submitted in September/strong/i/ppistrongRusfertide granted breakthrough designation for...
03/11/2025 22:05
Protagonist Therapeutics : Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
pstrong id=datelineNEWARK, CALIFORNIA / a href=https://www.accessnewswire.com/ACCESS Newswire/a / November 3, 2025 / /strongProtagonist Therapeutics, Inc. "Protagonist" or the "Company" announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY...
27/10/2025 12:35
Protagonist Therapeutics : Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
pistrongIcotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEMUC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo/strong/i/ppistrongUpdated ANTHEMUC data support Phase 3...
07/10/2025 14:10
Protagonist Therapeutics : Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
pistrongIcotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEMUC study/strong/i/ppistrongThese data support the promise...
17/09/2025 14:00
Protagonist Therapeutics : Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
pistrongIcotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONICADVANCE studies/strong/i/ppistrongIcotrokinra also showed sustained skin clearance and favorable safety profile in both adults and...
15/09/2025 16:45
Protagonist Therapeutics : Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
pstrong id=datelineNEWARK, CALIFORNIA / a href=https://www.accessnewswire.com/ACCESS Newswire/a / September 15, 2025 / /strongProtagonist Therapeutics, Inc. "Protagonist" or the "Company" announced that data from the Phase 2b ANTHEMUC study with icotrokinra in ulcerative colitis...
11/09/2025 14:00
Protagonist Therapeutics : Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
pistrongIcotrokinra is a firstinclass investigational targeted oral peptide that selectively blocks the IL23 receptor sup1/sup/strong/i/ppistrongFiling based on four Phase 3 studies that met all primary and coprimary endpoints. This unprecedented data package includes headtohead superiority...
26/08/2025 22:05
Protagonist Therapeutics : Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
pstrong id=datelineNEWARK, CALIFORNIA / a href=https://www.accessnewswire.com/ACCESS Newswire/a / August 26, 2025 / /strongProtagonist Therapeutics, Inc. "Protagonist" or the "Company" today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will...